Trump could either weaken the negotiations in a way that benefits the pharmaceutical industry, or try to achieve even deeper ...

We now have a glimpse behind the curtain of how Medicare arrives at so-called maximum fair prices of prescription drugs it ...

If big pharma was hoping that there would not be drug price negotiations under President Trump, they seem to have had their hopes dashed. That ...

CMS recently issued a statement saying that it's continuing the Medicare Drug Price Negotiation Program but is leaving the door open for potential changes. Experts weighed in on what changes could be ...

The Trump administration’s Centers for Medicare & Medicaid Services (CMS) has signaled that it will be revamping the process ...

Providers are sympathetic to Medicare enrollees’ concerns but don’t agree on their role in helping patients find less costly ...

Shares of Gilead Sciences Inc. surged over 4% in premarket trading on Wednesday following a solid fourth-quarter earnings ...

More than 65 million Americans rely on the program for their health insurance, with a significant proportion of those being ...

Lawmakers and providers need to step in before the program’s financial stability is threatened, Ron Williams, Diane Hansen, ...

Big drug maker Gilead expects to take a billion-dollar hit this year via drug-pricing provisions in the Inflation Reduction ...

Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...